Omnicell, Inc. (NASDAQ:OMCL) had its price target raised by analysts at Cantor Fitzgerald to $58.00 in a report issued on Friday. The brokerage presently has an “overweight” rating on the stock. Cantor Fitzgerald’s target price would indicate a potential upside of 14.17% from the stock’s current price.
Several other equities analysts also recently weighed in on OMCL. BidaskClub downgraded Omnicell from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Piper Jaffray Companies restated a “hold” rating and issued a $40.00 target price on shares of Omnicell in a research report on Sunday, July 30th. Craig Hallum raised their target price on Omnicell from $46.00 to $52.00 and gave the company a “buy” rating in a research report on Friday, July 28th. Dougherty & Co raised their target price on Omnicell from $45.00 to $49.00 and gave the company a “buy” rating in a research report on Friday, July 28th. Finally, Oppenheimer Holdings, Inc. restated a “buy” rating and issued a $55.00 target price on shares of Omnicell in a research report on Thursday, October 19th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Omnicell has a consensus rating of “Buy” and a consensus price target of $53.43.
Omnicell (NASDAQ OMCL) traded down 5.84% during mid-day trading on Friday, reaching $50.80. The company’s stock had a trading volume of 580,983 shares. The company’s market cap is $1.90 billion. The firm’s 50 day moving average is $51.05 and its 200-day moving average is $45.99. Omnicell has a 12-month low of $30.35 and a 12-month high of $55.40.
Omnicell (NASDAQ:OMCL) last released its earnings results on Thursday, October 26th. The company reported $0.42 earnings per share for the quarter, meeting the consensus estimate of $0.42. The business had revenue of $186.78 million for the quarter, compared to the consensus estimate of $192.45 million. Omnicell had a negative return on equity of 0.80% and a negative net margin of 0.51%. The business’s quarterly revenue was up 5.7% compared to the same quarter last year. During the same quarter last year, the business posted $0.40 earnings per share. Equities analysts anticipate that Omnicell will post $1.30 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This story was reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://www.com-unik.info/2017/10/29/cantor-fitzgerald-increases-omnicell-inc-omcl-price-target-to-58-00.html.
In related news, Chairman Randall A. Lipps sold 40,000 shares of the stock in a transaction that occurred on Tuesday, August 1st. The stock was sold at an average price of $49.76, for a total value of $1,990,400.00. Following the completion of the sale, the chairman now owns 196,551 shares of the company’s stock, valued at $9,780,377.76. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Robin Gene Seim sold 15,109 shares of the stock in a transaction that occurred on Tuesday, August 15th. The shares were sold at an average price of $50.86, for a total value of $768,443.74. Following the completion of the sale, the executive vice president now directly owns 58,144 shares of the company’s stock, valued at approximately $2,957,203.84. The disclosure for this sale can be found here. In the last ninety days, insiders sold 146,594 shares of company stock valued at $7,369,791. Insiders own 3.77% of the company’s stock.
Large investors have recently bought and sold shares of the stock. California Public Employees Retirement System increased its holdings in shares of Omnicell by 4.2% in the second quarter. California Public Employees Retirement System now owns 81,200 shares of the company’s stock valued at $3,500,000 after purchasing an additional 3,300 shares during the last quarter. Bank of America Corp DE increased its stake in Omnicell by 79.7% during the first quarter. Bank of America Corp DE now owns 202,466 shares of the company’s stock worth $8,231,000 after acquiring an additional 89,817 shares during the last quarter. Oak Ridge Investments LLC increased its stake in Omnicell by 0.6% during the second quarter. Oak Ridge Investments LLC now owns 1,537,940 shares of the company’s stock worth $66,285,000 after acquiring an additional 8,491 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in Omnicell by 82.7% during the first quarter. Goldman Sachs Group Inc. now owns 88,926 shares of the company’s stock worth $3,615,000 after acquiring an additional 40,240 shares during the last quarter. Finally, GAM Holding AG acquired a new stake in Omnicell during the second quarter worth $2,866,000.
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
What are top analysts saying about Omnicell Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Omnicell Inc. and related companies.